De novo development of JAK2V617F-positive polycythemia vera following allogeneic hematopoietic stem cell transplantation: a report of two rare cases

Gulten Korkmaz

doi:10.48101/ujms.v131.14276

Gulten Korkmaz Department of Hematology, Ankara Bilkent City Hospital, Çankaya/Ankara, Turkey

DOI: https://doi.org/10.48101/ujms.v131.14276

Keywords: Polycythemia vera, allogeneic HSCT, JAK2, CML, MDS

Abstract

Introduction: Post-transplant erythrocytosis following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare and has been reported mainly in patients with aplastic anemia and, less frequently, after transplantation for other hematologic conditions. Here, we present two cases of JAK2V617F-positive polycythemia vera (PV) developing after allo-HSCT performed for chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS).

Case presentations: Case 1: The patient, who underwent allo-HSCT for the diagnosis of MDS. He was diagnosed with JAK2V617F-positive PV, 48 months after transplantation. Case 2: The patient with chronic-phase CML underwent allo-HSCT while in hematologic remission. Approximately 10 years later, the patient was diagnosed with JAK2V617F-positive PV.

Discussion: Possible explanations for the development of a JAK2V617F mutation after allo-HSCT include the expansion of a pre-existing but clinically silent mutant clone in the donor, or the emergence of de novo mutations in donor or recipient cells as a result of proliferative stress, immunosuppression, or prior chemotherapy.

Downloads

Download data is not yet available.

References

1.
Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int. 2003;63:1187–94. doi: 10.1046/j.1523-1755.2003.00850.x

2.
Abdelrahman M, Rafi A, Ghacha R, Qayyum T, Karkar A. Post-transplant erythrocytosis: a review of 47 renal transplant recipients. Saudi J Kidney Dis Transpl. 2004;15:433–9.

3.
Ayas M, Siddiqui K, Al-Musa A, El-Solh H, Al-Jefri A, Al-Ahmari A, et al. Erythrocytosis post allogeneic stem cell transplantation, an observational study of hemoglobin levels on long-term follow up post transplantation in patients with Fanconi or acquired aplastic anemia. Blood. 2013;122:4643. doi: 10.1182/blood.V122.21.4643.4643

4.
Chaudhry QUN, Ahmed P, Satti HS, Satti TM, Mahmood SK, Shahbaz N, et al. Post allogeneic hematopoietic cell transplant erythrocytosis in aplastic anemia: a review of 208 cases. Blood. 2017;130:5499.

5.
Atilla E, Topcuoglu P, Ataca P, Pekcan G, Bozdag SC, Yuksel MK, et al. A rare complication after allogeneic stem cell transplantation: post-transplant erythrocytosis. Clin Transplant. 2016;30:669–72. doi: 10.1111/ctr.12741

6.
Kibirova A, Najeeb S, Craig M. Acquired secondary erythrocytosis in long-term survivors of allogeneic hematopoietic stem cell transplantation. Blood. 2018;132:3422. doi: 10.1182/blood-2018-99-113592

7.
Portell CA, Sekeres MA, Rogers HJ, Tiu RV. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. Br J Haematol. 2012;157:266–7. doi: 10.1111/j.1365-2141.2011.08972.x

8.
Van Pelt K, Nollet F, Selleslag D, Knoops L, Constantinescu SN, Criel A, et al. The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation. Blood. 2008;112:921–2. doi: 10.1182/blood-2008-04-154708

9.
Antonioli E, Guglielmelli P, Poli G, Santini V, Bosi A, Vannucchi AM. Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood. 2007;110:4620–1. doi: 10.1182/blood-2007-07-103267

10.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1

11.
Zanelli M, Bisagni A, Sanguedolce F, Broggi G, Fragliasso V, Zizzo M, et al. Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination. Front Oncol. 2024;13:1329298. doi: 10.3389/fonc.2023.1329298

12.
Deshmukh KG, Kelemen K. Lessons learned from donor cell-derived myeloid neoplasms: report of three cases and review of the literature. Life (Basel). 2022;12:559. doi: 10.3390/life12040559

13.
Suárez-González J, Martínez-Laperche C, Kwon M, Balsalobre P, Carbonell D, Chicano M, et al. Donor cell-derived hematologic neoplasms after hematopoietic stem cell transplantation: a systematic review. Biol Blood Marrow Transplant. 2018;24:1505–13. doi: 10.1016/j.bbmt.2018.01.033

14.
Walker AR, Rothberg PG, Liesveld JL. A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML. Bone Marrow Transplant. 2007;39:725–6. doi: 10.1038/sj.bmt.1705647

15.
Tosoni L, Fabbro D, Pizzano U, Mullai R, Morelli G, Franzoni A, et al. JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response. Ann Hematol. 2023;102:1279–80. doi: 10.1007/s00277-023-05187-5

16.
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, et al. Co-occurrence of Jak2-positive myelofibrosis and BCR-ABL-positive chronic myelogenous leukaemia treated with combination of tyrosine kinase inhibitors and ruxolitinib. Mediterr J Hematol Infect Dis. 2025;17:e2025023. doi: 10.4084/MJHID.2025.023

17.
Zhao Y, McCracken J, Wang E. Sequential development of JAK2^V617F and BCR-ABL1: a ‘double-hit’ myeloproliferative neoplasm with morphologic transition. J Hematopathol. 2021;14:251–3. doi: 10.1007/s12308-021-00458-4